Borderline Personality Disorder Clinical Trial
Official title:
An Ambispective Cohort Study on the Prognosis and Its Influencing Factors of Borderline Personality Disorder
Verified date | August 2023 |
Source | Wuhan Mental Health Centre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Borderline personality disorder (BPD) is a difficult chronic mental illness. This diagnosis is common in Western countries. Our researchers want to study the outcome and its influencing factors of BPD for the first time in China. Patients with BPD who had been hospitalized in Wuhan Mental Health Center were selected as the subjects. The researchers retrospectively collected the most recent hospitalization data of these patients, and then prospectively follow up them for 2 years to see how their condition will change. By analyzing all data, researchers hope to know deeply about the development law of this illness, and to provide evidence for releasing these patients' suffering.
Status | Active, not recruiting |
Enrollment | 270 |
Est. completion date | September 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of BPD based on ICD-10 (F60.3) Exclusion Criteria: - Comorbidity with severe physical disease - Comorbidity with neurological diseases such as epilepsy - Comorbidity with mental retardation |
Country | Name | City | State |
---|---|---|---|
China | Wuhan Mental Health Centre | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Wuhan Mental Health Centre |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | remission rate | The remission rate is calculated as the number of patients who no longer met the diagnostic criteria for BPD for at least 6 months divided by the total number of enrolled patients. The diagnostic tool is ICD-10 (F60.3). | After the first follow-up, patients will be followed up every 6 months, and the total follow-up time was 2 years. | |
Secondary | social disability | Social disability refers to the patient's occupation, family, social life, personal life and other aspects of functional deficits, using Social Disability Screening Schedule (SDSS) to assess. | After the first follow-up, patients will be followed up every 6 months, and the total follow-up time was 2 years. | |
Secondary | quality of life | Someone's quality of life is the extent to which their life is comfortable or satisfying. The study used WHOQOL-BREF to assess patients' quality of life in the physical, psychological, social relationship, and environmental domains. | After the first follow-up, patients will be followed up every 6 months, and the total follow-up time was 2 years. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Active, not recruiting |
NCT04587518 -
Five Factor Model Treatment for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Completed |
NCT03677037 -
The Short-Term MBT Project
|
Phase 3 | |
Not yet recruiting |
NCT05989529 -
Delving Into Borderline Personality Disorder Clinical Trial Experiences
|
||
Completed |
NCT02518906 -
Evaluation of AIT Study
|
N/A | |
Completed |
NCT02068326 -
MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT02108990 -
Acetaminophen and Social Processes
|
Phase 2 | |
Not yet recruiting |
NCT01683136 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder
|
N/A | |
Completed |
NCT01635556 -
Evaluation of a Modified Dialectical Behavior Therapy Program
|
N/A | |
Completed |
NCT02988037 -
Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study
|
N/A | |
Completed |
NCT02397031 -
Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder
|
N/A | |
Terminated |
NCT01103180 -
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
|
Phase 2 | |
Terminated |
NCT01212588 -
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
|
Phase 2 | |
Terminated |
NCT00539188 -
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
|
Phase 2 | |
Recruiting |
NCT05398627 -
Neurofeedback for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT03994510 -
SHame prOpensity in bOrderline Personality Disorder
|
N/A | |
Recruiting |
NCT06005129 -
Personality Change Study for Borderline Personality Disorder
|
N/A |